Shortening Radiation Course Duration Using Simultaneous Integrated Boost With Lower Intensity Elective Nodal Dosing and Concurrent Chemotherapy for High-Risk Anal Squamous Cell Carcinoma (SSIBLING)
Shortening Radiation Course Duration Via Simultaneous Integrated Boost With Lower Intensity Elective Nodal Dosing While Giving Concurrent Chemotherapy for High-risk Anal Squamous Cell Carcinoma - a Phase 2 Study
This phase 2 single-arm study will evaluate whether a shortened course of mildly hypofractionated radiation therapy given with standard concurrent chemotherapy (mitomycin C and capecitabine) can provide acceptable tumor control in patients with high-risk non-metastatic anal squamous cell carcinoma. Standard chemoradiation for anal cancer typically requires approximately 5.5 to 6 weeks of daily radiation, which can create substantial logistical burden for patients and caregivers, particularly those in rural settings.
The investigational approach uses a 23-fraction radiation regimen designed to shorten treatment duration while maintaining biologically equivalent tumor-directed dosing compared with standard treatment. The primary question is whether this shorter chemoradiation regimen can achieve an acceptable 6-month complete clinical response rate while maintaining manageable toxicity.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Standard chemoradiation for high-risk non-metastatic anal squamous cell carcinoma typically requires approximately 27 to 30 fractions of radiation delivered over 5.5 to 6 weeks with concurrent chemotherapy. While effective, this prolonged treatment course creates substantial logistical burden for patients and caregivers, particularly for those living in rural regions with limited access to radiation oncology facilities.
This phase 2, single-arm study evaluates a shortened hypofractionated chemoradiation approach designed to reduce treatment duration while maintaining biologically comparable tumor-directed dosing relative to conventional treatment regimens. The investigational radiation regimen uses a simultaneous integrated boost (SIB) approach delivering 23 fractions over approximately 4.5 weeks, with reduced elective nodal dosing and concurrent standard-of-care chemotherapy consisting of mitomycin C and capecitabine.
The study focuses on patients with high-risk non-metastatic anal squamous cell carcinoma, including larger primary tumors and/or node-positive disease, a population for whom treatment de-escalation strategies are generally not appropriate. The primary objective is to evaluate whether this shortened regimen achieves an acceptable 6-month complete clinical response rate. Secondary objectives include assessment of survival outcomes, disease control, treatment interruptions, clinician- and patient-reported toxicity, quality of life, and treatment burden.
Exploratory correlative analyses will evaluate circulating tumor DNA (ctDNA) collected at protocol-specified time points to assess correlations between circulating biomarkers and clinical outcomes. The study also includes optional qualitative patient and caregiver interviews to better understand treatment experience and logistical burden associated with cancer therapy.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Chris Anker, MD
- 전화번호: 1 (802) 656-2021
- 이메일: chris.anker@uvmhealth.org
연구 장소
-
-
Vermont
-
Burlington, Vermont, 미국, 05401
- University of Vermont Medical Center
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Age 18 years or older
- Histologically or cytologically confirmed non-metastatic anal squamous cell carcinoma meeting one of the following criteria:
T2 tumor measuring ≥4 cm T3 or T4 disease Any node-positive disease
- Patients with HPV-associated (p16-positive) perianal cancer are eligible if the tumor extends to the anal verge
- Karnofsky Performance Status >60
- Creatinine clearance >30 mL/min
- Considered by the investigator to be appropriate candidates for concurrent capecitabine and mitomycin C chemotherapy
- Ability to understand and willingness to provide informed consent
- For participants of childbearing potential: negative pregnancy test or documented absence of pregnancy per institutional standard within 14 days prior to registration
- Participants of reproductive potential must agree to use adequate contraception during study treatment and for 90 days after completion of therapy
Exclusion Criteria:
- Prior pelvic radiation therapy
- Uncontrolled intercurrent illness that, in the opinion of the investigator, would prevent safe receipt of radiation therapy or capecitabine
- Prior or concurrent malignancy that, in the opinion of the investigator, could interfere with assessment of safety or efficacy
- Current receipt of another investigational agent for treatment of anal squamous cell carcinoma
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Experimental: Hypofractionated Chemoradiation
Participants receive mildly hypofractionated radiation therapy delivered in 23 fractions using a simultaneous integrated boost approach with concurrent standard-of-care mitomycin C and capecitabine chemotherapy.
|
Participants receive mildly hypofractionated radiation therapy delivered in 23 fractions using a simultaneous integrated boost approach, given concurrently with standard-of-care mitomycin C and capecitabine chemotherapy.
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Complete Clinical Response Rate at 6 Months
기간: 6 months after start of radiation therapy
|
Proportion of participants achieving complete clinical response, defined as absence of tumor and malignant ulceration in the anal canal and perianal skin on digital rectal examination and/or anoscopy, with resolution of palpable inguinal lymphadenopathy if present at baseline.
Biopsy may be used when clinically indicated to confirm persistent disease.
|
6 months after start of radiation therapy
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Colostomy-Free Survival
기간: 2 years
|
Time from completion of treatment to colostomy placement or last follow-up without colostomy.
|
2 years
|
|
Disease-Free Survival
기간: 2 years
|
Time from study registration to disease progression, recurrence, or death from any cause.
|
2 years
|
|
Locoregional Control
기간: 2 years
|
Proportion of participants without locoregional disease failure involving the primary tumor or regional lymph node sites.
|
2 years
|
|
Local Control Rate
기간: 2 years
|
Proportion of participants without local recurrence at the primary tumor site.
|
2 years
|
|
Regional Control Rate
기간: 2 years
|
Proportion of participants without recurrence in regional lymph node sites.
|
2 years
|
|
Elective Regional Control Rate
기간: 2 years
|
Proportion of participants without recurrence in electively treated nodal regions.
|
2 years
|
|
Distant Metastasis-Free Survival
기간: 2 years
|
Time from study registration to development of distant metastatic disease or death.
|
2 years
|
|
Overall Survival
기간: 2 years
|
Time from study registration to death from any cause.
|
2 years
|
|
Treatment Interruption Rate
기간: During treatment (approximately 5 weeks)
|
Proportion of participants experiencing interruption or delay in planned protocol treatment.
|
During treatment (approximately 5 weeks)
|
|
Treatment-Related Toxicity
기간: Baseline through 24 months
|
Incidence of clinician-reported treatment-related adverse events graded according to CTCAE version 6.0.
|
Baseline through 24 months
|
|
Patient-Reported Treatment-Related Symptoms
기간: Baseline through 24 months
|
Patient-reported gastrointestinal, genitourinary, skin, and functional symptoms assessed using PRO-CTCAE.
|
Baseline through 24 months
|
|
Fecal Incontinence Severity Index Score
기간: Baseline through 24 months
|
The Fecal Incontinence Severity Index is a patient-reported measure of fecal incontinence severity based on the frequency of accidental leakage of gas, mucus, liquid stool, and solid stool.
Total scores range from 0 to 61, with higher scores indicating more severe fecal incontinence.
|
Baseline through 24 months
|
|
Hazard Ratio for Clinical Recurrence According to HPV ctDNA Detection Status
기간: Baseline through 24 months
|
HPV ctDNA will be measured in serial plasma samples using a laboratory-based HPV ctDNA assay and categorized as detectable or undetectable. We will assess the correlation between baseline HPV ctDNA levels and selected clinical features via a Wilcoxon test. We will test for correlations between HPV ctDNA detection and recurrence-free survival using a landmark Cox proportional hazards model, with recurrence-free survival compared using the log-rank test Clinical recurrence will be based on radiographic imaging, endoscopic assessment, and/or clinical examination, as determined by the evaluating physician. HPV ctDNA detection will not be considered a recurrence event. |
Baseline through 24 months
|
|
Patient and Caregiver Treatment Experience Assessed Through Qualitative Interviews
기간: Approximately 3 months after treatment
|
Patient and caregiver experiences will be assessed using semi-structured Patient and Caregiver/Support Person Experience Interviews.
Interview responses will be reviewed to identify common themes related to treatment burden, convenience, travel requirements, caregiver impact, treatment tolerance, and perceptions of the shortened treatment course.
|
Approximately 3 months after treatment
|
|
Fecal Incontinence Quality of Life Scale Domain Scores
기간: Baseline through 24 months
|
The Fecal Incontinence Quality of Life Scale measures quality of life across four domains: lifestyle, coping/behavior, depression/self-perception, and embarrassment.
Domain scores range from 1 to 5, with higher scores indicating better quality of life.
|
Baseline through 24 months
|
|
Baseline HPV ctDNA Levels According to Selected Clinical Features
기간: Baseline
|
Baseline HPV ctDNA levels will be measured in plasma using a laboratory-based HPV ctDNA assay.
Correlations between baseline HPV ctDNA levels and selected demographic and disease-related clinical features will be assessed using a Wilcoxon test.
|
Baseline
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Christopher L Anker, MD, University of Vermont Cancer Center
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- UVMCC2604
- temp (기타 보조금/기금 번호: University of Vermont Cancer Center)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .